Protease Inhibition-An Established Strategy to Combat Infectious Diseases.
Int J Mol Sci
; 22(11)2021 May 28.
Article
in English
| MEDLINE | ID: covidwho-1256561
ABSTRACT
Therapeutic agents with novel mechanisms of action are urgently needed to counter the emergence of drug-resistant infections. Several decades of research into proteases of disease agents have revealed enzymes well suited for target-based drug development. Among them are the three recently validated proteolytic targets proteasomes of the malarial parasite Plasmodium falciparum, aspartyl proteases of P. falciparum (plasmepsins) and the Sars-CoV-2 viral proteases. Despite some unfulfilled expectations over previous decades, the three reviewed targets clearly demonstrate that selective protease inhibitors provide effective therapeutic solutions for the two most impacting infectious diseases nowadays-malaria and COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Plasmodium falciparum
/
Protease Inhibitors
/
Proteasome Endopeptidase Complex
/
Drug Development
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Malaria
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Ijms22115762
Similar
MEDLINE
...
LILACS
LIS